Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking. METHODS: In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety. RESULTS: At the last measurement, the mean (+/-SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium. CONCLUSIONS: Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is also approved for treatment in men and women at high risk of fracture with osteoporosis associated with sustained systemic glucocorticoid therapy [91].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [91]
In the citing paper
“In support of this notion, it is reported that anabolic agent, hPTH (1-34), is superior to bisphosphonates in increasing spine and hip BMD and reduces the incidence of new vertebral fractures in glucocorticoid-induced osteoporosis (GIOP) populations for both men and women [11, 47-49].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [11]
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Self-citationIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Research works printed but not linked: 2
- Sambrook PN, 2001, Aust Fam Physician, 30, 793
- Mudano A, 2001, J Rheumatol, 28, 1298
Cited by
Items 201–300 of 910
Koh, J. H., Myong, J., Yoo, J., Lim, Y. W., Lee, J., Kwok, S., Park, S.-H., & Ju, J. H. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4169-y · Cited by 57
Bone management in hematologic stem cell transplant recipients
Kendler, D. L., Body, J., Brandi, M. L., Broady, R. C., Cannata-Andía, J. B., Cannata‐Ortiz, J., Maghraoui, A. E., Guglielmi, G., Hadji, P., Pierroz, D. D., et al. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4669-4 · Cited by 47
Lan, G.-B., Xie, X.-B., Peng, L.-K., Liu, L., Song, L., & Dai, H.-L. (2015) · BioMed Research International · doi:10.1155/2015/413169 · Cited by 46
Paccou, J., Yavropoulou, M. P., Naciu, A. M., Chandran, M., Messina, O. D., Rolvien, T., CAREY, J. J., D’Oronzo, S., Anastasilakis, A. D., Saag, K. G., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae146 · Cited by 52
Self-citationFarahmand, P., Marín, F., Hawkins, F. G., Moericke, R., Ringe, J. D., Glüer, C.-C., Παπαϊωάννου, Ν., Minisola, S., Martínez, G., Solé, J. M. N., et al. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2379-5 · Cited by 51
Self-citationManagement of glucocorticoid-induced osteoporosis
Messina, O. D., Vidal, L. F., Vidal, M., Bultink, I. E. M., Raterman, H. G., & Lems, W. F. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01823-0 · Cited by 48
Clinical and Basic Aspects of Glucocorticoid Action in Bone
Kream, B. E., Graves, L., & Lukert, B. P. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00061-6 · Cited by 47
Kirigaya, D., Nakayama, T., Ishizaki, T., Ikeda, S., & Satoh, T. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.5266 · Cited by 44
Progress in osteoporosis and fracture prevention: focus on postmenopausal women
Saag, K. G., & Geusens, P. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2815 · Cited by 50
Self-citationBurshell, A., Moericke, R., Correa‐Rotter, R., Chen, P., Warner, M. R., Dalsky, G. P., Taylor, K. A., & Krege, J. H. (2010) · Bone · doi:10.1016/j.bone.2009.12.032 · Cited by 45
Self-citationDenosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis
Shane, E. J., Shiau, S., Recker, R. R., Lappe, J. M., Agarwal, S., Kamanda‐Kosseh, M., Bucovsky, M., Stubby, J., & Cohen, A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab850 · Cited by 46
Self-citationHardy, R., & Cooper, M. S. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.007 · Cited by 52
Cohen, A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.09.007 · Cited by 52
High-resolution structures of a heterochiral coiled coil
Mortenson, D. E., Steinkruger, J. D., Kreitler, D. F., Perroni, D. V., Sorenson, G. P., Huang, L., Mittal, R., Yun, H. G., Travis, B. R., Mahanthappa, M. K., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507918112 · Cited by 43
Sugiura, T., Kashii, M., Matsuo, Y., Morimoto, T., Honda, H., Kaito, T., Iwasaki, M., & Yoshikawa, H. (2014) · The Spine Journal · doi:10.1016/j.spinee.2014.08.001 · Cited by 44
Glucocorticoid induced osteoporosis
Hu, K., & Adachi, J. D. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1617131 · Cited by 48
New anabolic therapies for osteoporosis
Minisola, S., Cipriani, C., Occhiuto, M., & Pepe, J. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1719-4 · Cited by 43
Napoli, N., Langdahl, B. L., Ljunggren, Ö., Lespessailles, É., Kapetanos, G. A., Kocjan, T., Nikolic, T., Eiken, P., Petto, H., Moll, T., et al. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0437-x · Cited by 43
Self-citationKorean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis
Park, S. Y., Gong, H. S., Kim, K. M., Kim, D., Kim, H. Y., Jeon, C. H., Ju, J. H., Lee, S., Park, D. A., Sung, Y., et al. (2018) · Journal of Bone Metabolism · doi:10.11005/jbm.2018.25.4.195 · Cited by 46
Treatment options for glucocorticoid-induced osteoporosis
Chiodini, I., Merlotti, D., Falchetti, A., & Gennari, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1721467 · Cited by 48
Osteopathy in mild adrenal Cushing’s syndrome and Cushing disease
Frara, S., Allora, A., di Filippo, L., Formenti, A. M., Loli, P., Polizzi, E., Tradati, D., Ulivieri, F. M., & Giustina, A. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101515 · Cited by 47
Update on Glucocorticoid-Induced Osteoporosis
Maricic, M. J. (2011) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2011.07.003 · Cited by 47
Update on Glucocorticoid Induced Osteoporosis
Cho, S., & Sung, Y. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1021 · Cited by 45
Role of bone-forming agents in the management of osteoporosis
McClung, M. R. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01708-8 · Cited by 46
The molecular etiology and treatment of glucocorticoid-induced osteoporosis
Peng, C.-H., Lin, W.-Y., Yeh, K., Chen, I., Wu, W., & Lin, M. (2021) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_233_20 · Cited by 45
Parathyroid hormone treatment for osteoporosis
Cosman, F. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32831a46d6 · Cited by 44
Ip, T., Cheung, S.-K. W., Cheung, T.-C., Choi, T.-C., Chow, S.-L. E., Ho, Y.-Y. A., Kan, S.-Y. A., Kung, W. C. A., Lee, K.-K., Leung, K. L. F., et al. (2013) · PubMed · Cited by 51
Maher, J. R., Berger, A. J., Takahata, M., & Awad, H. A. (2011) · Journal of Biomedical Optics · doi:10.1117/1.3613933 · Cited by 42
Mammalian target of rapamycin as a therapeutic target in osteoporosis
Shen, G., Ren, H. J., Qiu, T., Zhang, Z., Zhao, W., Yu, X., Huang, J., Tang, J., Liang, D., Yao, Z., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26161 · Cited by 43
Sahbani, K., Cardozo, C. P., Bauman, W. A., & Tawfeek, H. A. W. (2019) · Physiological Reports · doi:10.14814/phy2.14225 · Cited by 42
Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
Cosman, F., & Dempster, D. W. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00663-1 · Cited by 43
Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
Tonk, C. H., Shoushrah, S. H., Babczyk, P., Khaldi-Hansen, B. E., Schulze, M., Herten, M., & Tobiasch, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031393 · Cited by 49
Bone health in persons with haemophilia
Kempton, C. L., Antoniucci, D. M., & Rodriguez-Merchan, E. C. (2015) · Haemophilia · doi:10.1111/hae.12736 · Cited by 47
Management of osteoporosis in a pre-menopausal woman
Bhalla, A. K. (2010) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2010.01.006 · Cited by 44
Anabolic Therapies for Osteoporosis
Uihlein, A. V., & Leder, B. Z. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.05.002 · Cited by 43
Anabolic Therapy in Glucocorticoid-Induced Osteoporosis
Sambrook, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejme0706770 · Cited by 39
Humphrey, M. B., Russell, L., Danila, M. I., Fink, H. A., Guyatt, G. H., Cannon, M. D., Caplan, L., Gore, S., Grossman, J., Hansen, K. E., et al. (2023) · Arthritis Care & Research · doi:10.1002/acr.25240 · Cited by 45
for the Joint IOF–ECTS GIO Guidelines Working Group, Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J. P., Boonen, S., Borgström, F., Cooper, C. C., Díez‐Pérez, A., Eastell, R., et al. (2012) · Archives of Osteoporosis · doi:10.1007/s11657-012-0070-7 · Cited by 38
Self-citationde Castro, L. F., Lozano, D., Dapía, S., Portal‐Núñez, S., Caeiro, J. R., Gómez‐Barrena, E., & Esbrit, P. (2009) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0355 · Cited by 40
Shen, L., Xie, X., Su, Y., Luo, C., Zhang, C., & Zeng, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026267 · Cited by 38
Yu, K.-H., Chen, H.-H., Cheng, T.-T., Jan, Y.-J., Weng, M.-Y., Lin, Y.-J., Chen, H.-A., Cheng, J.-T., Huang, K.-Y., Li, K.-J., et al. (2022) · Medicine · doi:10.1097/md.0000000000028501 · Cited by 47
Glucocorticoids induce autophagy in rat bone marrow mesenchymal stem cells
Wang, L., Fan, J., Lin, Y., Guo, Y., Gao, B., SHI, Q.-Y., Wei, B.-Y., Chen, L., Yang, L., Liu, J., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3099 · Cited by 39
Cohen, A., Shiau, S., Nair, N., Recker, R. R., Lappe, J. M., Dempster, D. W., Nickolas, T. L., Zhou, H., Agarwal, S., Kamanda‐Kosseh, M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa489 · Cited by 36
Self-citationClinical role of bisphosphonate therapy
Fogelman, I., & Hampson (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s24783 · Cited by 45
2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2011.05.007 · Cited by 45
Karras, D., Stoykov, I., Lems, W. F., Langdahl, B. L., Ljunggren, Ö., Barrett, A., Walsh, J. B., Fahrleitner‐Pammer, A., Rajzbaum, G., Jakob, F. J., et al. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.110947 · Cited by 39
Self-citationEastell, R., Chen, P., Saag, K. G., Burshell, A., Wong, M., Warner, M. R., & Krege, J. H. (2010) · Bone · doi:10.1016/j.bone.2009.12.021 · Cited by 38
Self-citationControl of bone resorption in mice by Schnurri-3
Wein, M. N., Jones, D. C., Shim, J., Aliprantis, A. O., Sulyanto, R. M., Lazarevic, V., Poliachik, S. L., Gross, T. S., & Glimcher, L. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205848109 · Cited by 37
Significant association between parathyroid hormone and uric acid level in men
Chin, K., Ima-Nirwana, S., & Ngah, W. Z. W. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s90233 · Cited by 35
Glucocorticoid-Induced Osteoporosis: A Review
Bouvard, B., Legrand, É., Audran, M., & Chappard, D. (2009) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9051-9 · Cited by 40
Hauser, B., Alonso, N., & Riches, P. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071403 · Cited by 40
Updated Recommendations for the Diagnosis and Management of Osteoporosis: A Local Perspective
Raef, H., Al-Bugami, M., Balhareth, S. S., Moawad, M. A., El-Shaker, M., Hussain, A. N., Al-Shaikh, A., & Al-Badawi, I. A. (2011) · Annals of Saudi Medicine · doi:10.4103/0256-4947.77502 · Cited by 38
Identification of osteogenic progenitor cell-targeted peptides that augment bone formation
Jiang, M., Liu, R., Liu, L., Kot, A., Liu, X., Xiao, W., Jia, J., Li, Y., Lam, K. S., & Yao, W. (2020) · Nature Communications · doi:10.1038/s41467-020-17417-9 · Cited by 37
Male osteoporosis: new insights in an understudied disease
Haney, E. M., & Bliziotes, M. M. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283025eb0 · Cited by 41
The use of PTH in the treatment of osteoporosis
Borba, V. Z. C., & Mañas, N. C. P. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000200018 · Cited by 34
Oswald, A. J., Berg, J., Milne, G., & Ralston, S. H. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9788-5 · Cited by 35
Anabolic agents: what is beyond osteoporosis?
Liu, Y., Levack, A. E., Marty, E., Or, O., Samuels, B., Redko, M., & Lane, J. M. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4507-8 · Cited by 34
Idiopathic Osteoporosis in Men
Gennari, L., & Bilezikian, J. P. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0164-1 · Cited by 36
New and developing pharmacotherapy for osteoporosis in men
Gennari, L., & Bilezikian, J. P. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1428559 · Cited by 38
Glucocorticoid-induced osteoporosis in men
Adler, R. A., & Hochberg, M. C. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03346716 · Cited by 32
Ko, J., Wu, R., Kuo, S., Chen, M., Yeh, D., Ke, H., Wu, S., & Wang, F. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33457 · Cited by 32
Hirooka, Y., Nozaki, Y., Inoue, A., Li, J., Shiga, T., Kishimoto, K., Sugiyama, M., Kinoshita, K., Funauchi, M., & Matsumura, I. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100293 · Cited by 35
A Review of Osteoporosis Management in Younger Premenopausal Women
McLendon, A. N., & Woodis, C. B. (2013) · Women s Health · doi:10.2217/whe.13.73 · Cited by 32
Evaluation and Management of the Premenopausal Woman with Low BMD
Cohen, A., & Shane, E. J. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0161-4 · Cited by 37
Self-citationCeliac Disease and Its Role in the Development of Metabolic Bone Disease
Micić, D., Rao, V. L., & Semrad, C. E. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.06.005 · Cited by 37
Management of comorbidities in haemophilia
Kempton, C. L., Makris, M., & Holme, P. A. (2020) · Haemophilia · doi:10.1111/hae.14013 · Cited by 34
Villa, J. C., Gianakos, A. L., & Lane, J. M. (2015) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-015-9469-1 · Cited by 38
Prevention of glucocorticoid induced bone changes with beta-ecdysone
Dai, W., Jiang, L., Lay, Y.-A. E., Chen, H., Jin, G., Zhang, H., Kot, A., Ritchie, R. O., Lane, N. E., & Yao, W. (2015) · Bone · doi:10.1016/j.bone.2015.01.001 · Cited by 30
Evaluation and Treatment of Osteoporosis
O’Connor, K. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.016 · Cited by 42
Nogueira, E., Costa, A. C., Santana, A., Guerra, J. O., Silva, S. M., Mil-Homens, C., & da Costa, A. G. (2011) · Transplantation · doi:10.1097/tp.0b013e3182247b98 · Cited by 30
Lina, I. A., Puvanesarajah, V., Liauw, J. A., Lo, S.-F. L., Santiago-Dieppa, D. R., Hwang, L. S., Mao, A. M., Bydon, A., Wolinsky, J., Sciubba, D. M., et al. (2013) · Spine · doi:10.1097/brs.0000000000000169 · Cited by 30
Alessandro de, S. I. R. E., Lippi, L., Aprile, V., Calafiore, D., Folli, A., D’Abrosca, F., Moalli, S., Lucchi, M., Ammendolia, A., & Invernizzi, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101626 · Cited by 33
Wu, R., Lin, T.-P., Ko, J., Yeh, D., Chen, M.-W., Ke, H.-C., Wu, S.-L., & Wang, F. (2011) · Bone · doi:10.1016/j.bone.2011.08.022 · Cited by 30
Optimum management of glucocorticoid-treated patients
Trikudanathan, S., & McMahon, G. T. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0791 · Cited by 31
Papierska, L., Rabijewski, M., Kasperlik-Zaluska, A. A., & Zgliczyński, W. (2012) · Advances in Medical Sciences · doi:10.2478/v10039-011-0060-9 · Cited by 30
Adverse bone effects of medications used to treat non-skeletal disorders
Watts, N. B. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4171-4 · Cited by 32
Geusens, P., Roux, C., Reid, D. M., Lems, W. F., Adami, S., Adachi, J. D., Sambrook, P. N., Saag, K. G., Lane, N. E., & Hochberg, M. C. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0773 · Cited by 31
Self-citationWhitmarsh, T., Treece, G. M., Gee, A. H., & Poole, K. E. S. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2454 · Cited by 30
Extremophilic proteases as novel and efficient tools in short peptide synthesis
Białkowska, A. M., Morawski, K., & Florczak, T. (2017) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-017-1961-9 · Cited by 30
Medical optimization of lumbar fusion in the osteoporotic patient
Morris, M. T., Tarpada, S. P., Tabatabaie, V., & Cho, W. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0427-7 · Cited by 29
Efficacy and Safety of First- and Second-Line Drugs to Prevent Glucocorticoid-Induced Fractures
Ding, L., Hu, J., Wang, D., Liu, Q., Mo, Y., Tan, X., & Wen, F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz023 · Cited by 32
Glucocorticoids and the risk of osteoporosis
Caplan, L., & Saag, K. G. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740330802648194 · Cited by 30
Self-citationGlucocorticoid-induced osteoporosis and parathyroid hormone.
Carpinteri, R., Porcelli, T., Mejia, C., Patelli, I., Bilezikian, J. P., CANALIS, E. M., Angeli, A., Giustina, A., & Mazziotti, G. (2010) · PubMed · Cited by 35
Glucocorticoid-Induced Bone Fragility Is Prevented in Female Mice by Blocking Pyk2/Anoikis Signaling
Sato, A. Y., Cregor, M. D., McAndrews, K., Li, T., Condon, K. W., Plotkin, L. I., & Bellido, T. (2019) · Endocrinology · doi:10.1210/en.2019-00237 · Cited by 29
Taylor, A. D., & Saag, K. G. (2019) · Core evidence · doi:10.2147/ce.s172820 · Cited by 30
Self-citationLuo, C., Qin, S.-X., Wang, Q., Li, Y.-F., Qu, X., Yue, C., Hu, L., Sheng, Z., Wang, X.-B., & Xia, W. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01910-7 · Cited by 32
Therapy of Osteoporosis in Men with Teriparatide
Cusano, N. E., Costa, A. G., Silva, B. C. C., & Bilezikian, J. P. (2011) · Journal of Osteoporosis · doi:10.4061/2011/463675 · Cited by 29
Clinical Practice Guideline for CKD-MBD
The Japanese Society for Dialysis Therapy (2012) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.45.301 · Cited by 29
Catalano, A., Vita, G. L., Russo, M., Vita, G. L., Lasco, A., Morabito, N., & Messina, S. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3761-x · Cited by 27
Recommendations by the Spanish Society of Rheumatology on Osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Rodríguez, G. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.09.011 · Cited by 40
Profile of teriparatide in the management of postmenopausal osteoporosis
Sikon, A. L., & Batur (2010) · International Journal of Women s Health · doi:10.2147/ijwh.s4919 · Cited by 27
Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis
Bonafede, M., Shi, N., Bower, A. G., Barron, R. L., Grauer, A., & Chandler, D. (2015) · Osteoporosis International · doi:10.1007/s00198-014-2971-3 · Cited by 29
Therapeutic approaches to myeloma bone disease: An evolving story
Longo, V., Brunetti, O., D’Oronzo, S., Dammacco, F., & Silvestris, F. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.004 · Cited by 27
Recognition and management of polymyalgia rheumatica and giant cell arteritis.
Caylor, T. L., & Perkins, A. (2013) · PubMed · Cited by 36
Liu, J., Lu, C., Wu, X., Zhang, Z., Li, J., Guo, B., Li, D., Liang, C., Dang, L., Pan, X., et al. (2017) · Scientific Reports · doi:10.1038/srep41295 · Cited by 27
Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice
Adami, G., Rahn, E. J., & Saag, K. G. (2019) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x19876468 · Cited by 30
Self-citationBody, J., Marín, F., Kendler, D. L., Zerbini, C. A. F., López‐Romero, P., Moericke, R., Casado, E., Fahrleitner‐Pammer, A., Stepan, J. J., Lespessailles, É., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05463-4 · Cited by 31
Self-citationPereira, R. M. R., Perez, M. O., de Paula, A. P., Moreira, C., Castro, C. H. D. M., Zerbini, C. A. F., Domiciano, D. S., de Azevedo, E., de Mendonça, L. M. C., Shinzato, M. M., et al. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00902-z · Cited by 30
Yu, E. W.-Y., Neer, R. M., Lee, H., Wyland, J. J., de la Paz, A. V., Davis, M. C., Okazaki, M., & Finkelstein, J. S. (2010) · Bone · doi:10.1016/j.bone.2010.11.012 · Cited by 26
Su, C.-H., Tu, P., Yang, T.-C., & Tseng, Y. (2011) · Journal of Spinal Disorders & Techniques · doi:10.1097/bsd.0b013e31823f6298 · Cited by 26
Metadata
- Authors
- Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R.
- Affiliations
- University of Alabama at Birmingham (US)
- Columbia University (US)
- KU Leuven (BE)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2028-2039
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2042007405
- Cited by
- 914
- References
- 40
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 36 · 2023: 32 · 2022: 45 · 2021: 56 · 2020: 43 · 2019: 38 · 2018: 53 · 2017: 35 · 2016: 33 · 2015: 51 · 2014: 49 · 2013: 59 · 2012: 61
- FWCI
- 63.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- teriparatide, alendronate, glucocorticoid-induced osteoporosis, bisphosphonates, bone mineral density, vertebral fractures, non-vertebral fractures, fracture risk, serum calcium, bone turnover markers, anabolic therapy
- MeSH terms
- Aged, Aged, 80 and over, Calcium, Double-Blind Method, Female, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Risk, Biomarkers, Bone Density, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.